Patents by Inventor Robert F. Kaiko

Robert F. Kaiko has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20100291203
    Abstract: The invention is directed in part to oral dosage forms comprising a combination of an orally analgesically effective amount of an opioid agonist and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist to provide a combination product which is analgesically effective when the combination is administered orally, but which is aversive in a physically dependent subject. Preferably, the amount of opioid antagonist included in the combination product provides at least a mildly negative, “aversive” experience in physically dependent addicts (e.g., precipitated abstinence syndrome).
    Type: Application
    Filed: May 24, 2010
    Publication date: November 18, 2010
    Applicant: PURDUE PHARMA L.P.
    Inventors: ROBERT F. KAIKO, Robert D. Colucci
  • Publication number: 20100209514
    Abstract: Patients are treated with 24-hour oral sustained release opioid formulations which, upon administration, provide an initially rapid opioid absorption such that the minimum effective analgesic concentration of the opioid is more quickly achieved. These sustained release opioid formulations include an effective amount of at least one retardant material to cause said opioid analgesic to be released at a such a rate as to provide an analgesic effect after oral administration to a human patient for at least about 24 hours, and are characterized by providing an absorption half-life from 1 to about 8 hours. A method of titrating a human patient utilizing these sustained release opioid formulations is also disclosed.
    Type: Application
    Filed: December 8, 2009
    Publication date: August 19, 2010
    Inventors: Richard S. Sackler, Robert F. Kaiko, Paul Goldenheim
  • Publication number: 20100209351
    Abstract: Patients are treated with 24-hour oral sustained release opioid formulations which, upon administration, provide an initially rapid opioid absorption such that the minimum effective analgesic concentration of the opioid is more quickly achieved. These sustained release opioid formulations include an effective amount of at least one retardant material to cause said opioid analgesic to be released at a such a rate as to provide an analgesic effect after oral administration to a human patient for at least about 24 hours, and are characterized by providing an absorption half-life from 1 to about 8 hours. A method of titrating a human patient utilizing these sustained release opioid formulations is also disclosed.
    Type: Application
    Filed: December 8, 2009
    Publication date: August 19, 2010
    Inventors: Richard S. Sackler, Robert F. Kaiko, Paul Goldenheim
  • Patent number: 7749542
    Abstract: The invention is directed in part to oral dosage forms comprising a combination of an orally analgesically effective amount of an opioid agonist and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist to provide a combination product which is analgesically effective when the combination is administered orally, but which is aversive in a physically dependent subject. Preferably, the amount of opioid antagonist included in the combination product provides at least a mildly negative, “aversive” experience in physically dependent addicts (e.g., precipitated abstinence syndrome).
    Type: Grant
    Filed: July 28, 2008
    Date of Patent: July 6, 2010
    Assignee: Purdue Pharma LP
    Inventors: Robert F. Kaiko, Robert D. Colucci
  • Publication number: 20080292694
    Abstract: The invention is directed in part to oral dosage forms comprising a combination of an orally analgesically effective amount of an opioid agonist and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist to provide a combination product which is analgesically effective when the combination is administered orally, but which is aversive in a physically dependent subject. Preferably, the amount of opioid antagonist included in the combination product provides at least a mildly negative, “aversive” experience in physically dependent addicts (e.g., precipitated abstinence syndrome).
    Type: Application
    Filed: July 28, 2008
    Publication date: November 27, 2008
    Applicant: PURDUE PHARMA L.P.
    Inventors: Robert F. Kaiko, Robert D. Colucci
  • Patent number: 7419686
    Abstract: The invention is directed in part to oral dosage forms comprising a combination of an orally analgesically effective amount of an opioid agonist and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist to provide a combination product which is analgesically effective when the combination is administered orally, but which is aversive in a physically dependent subject. Preferably, the amount of opioid antagonist included in the combination product provides at least a mildly negative, “aversive” experience in physically dependent addicts (e.g., precipitated abstinence syndrome).
    Type: Grant
    Filed: December 26, 2006
    Date of Patent: September 2, 2008
    Assignee: Purdue Pharma L.P.
    Inventors: Robert F. Kaiko, Robert D. Colucci
  • Patent number: 7172767
    Abstract: The invention is directed in part to oral dosage forms comprising a combination of an orally analgesically effective amount of an opioid agonist and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist to provide a combination product which is analgesically effective when the combination is administered orally, but which is aversive in a physically dependent subject. Preferably, the amount of opioid antagonist included in the combination product provides at least a mildly negative, “aversive” experience in physically dependent addicts (e.g., precipitated abstinence syndrome).
    Type: Grant
    Filed: October 27, 2003
    Date of Patent: February 6, 2007
    Assignee: Purdue Pharma L.P.
    Inventors: Robert F. Kaiko, Robert D. Colucci
  • Publication number: 20040086561
    Abstract: The invention is directed in part to oral dosage forms comprising a combination of an orally analgesically effective amount of an opioid agonist and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist to provide a combination product which is analgesically effective when the combination is administered orally, but which is aversive in a physically dependent subject. Preferably, the amount of opioid antagonist included in the combination product provides at least a mildly negative, “aversive” experience in physically dependent addicts (e.g., precipitated abstinence syndrome).
    Type: Application
    Filed: October 27, 2003
    Publication date: May 6, 2004
    Inventors: Robert F. Kaiko, Robert D. Colucci
  • Patent number: 6696066
    Abstract: The invention is directed in part to oral dosage forms comprising a combination of an orally analgesically effective amount of an opioid agonist and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist to provide a combination product which is analgesically effective when the combination is administered orally, but which is aversive in a physically dependent subject. Preferably, the amount of opioid antagonist included in the combination product provides at least a mildly negative, “aversive” experience in physically dependent addicts (e.g., precipitated abstinence syndrome).
    Type: Grant
    Filed: September 16, 2002
    Date of Patent: February 24, 2004
    Assignee: Euro-Celtique S.A.
    Inventors: Robert F. Kaiko, Robert D. Colucci
  • Publication number: 20030198675
    Abstract: A method of effectively treating pain in humans is achieved by administering buprenorphine in accordance with first order kinetics over an initial three-day dosing interval, such that a maximum plasma concentration from about 20 pg/ml to about 1052 pg/ml is attained, and thereafter maintaining the administration of buprenorphine for at least an additional two-day dosing interval in accordance with substantially zero order kinetics, such that the patients experience analgesia throughout the at least two-day additional dosing interval.
    Type: Application
    Filed: March 28, 2003
    Publication date: October 23, 2003
    Inventors: Robert F. Reder, Paul D. Goldenheim, Robert F. Kaiko
  • Patent number: 6627635
    Abstract: The invention relates in part to a method of reducing the abuse potential of an oral dosage form of an opioid analgesic, wherein an analgesically effective amount of an orally active opioid agonist is combined with an opioid antagonist into an oral dosage form which would require at least a two-step extraction process to be separated from the opioid agonist, the amount of opioid antagonist including being sufficient to counteract opioid effects if extracted together with the opioid agonist and administered parenterally.
    Type: Grant
    Filed: March 22, 2001
    Date of Patent: September 30, 2003
    Assignee: Euro-Celtique S.A.
    Inventors: Philip J. Palermo, Robert F. Kaiko, Robert D. Colucci
  • Publication number: 20030181475
    Abstract: A method of treating depression using transdermal delivery of buprenorphine is described. In one embodiment, the method employs transdermal patches comprising buprenorphine, preferably escalating incrementally the buprenorphine dose to a level where one or more symptoms of depression are alleviated. The method is particularly suitable for patients suffering from refractory depression, or for patients suffering from both depression and pain.
    Type: Application
    Filed: March 20, 2003
    Publication date: September 25, 2003
    Applicant: EURO-CELTIQUE S.A.
    Inventors: Robert F. Kaiko, Ramiro Sanchez
  • Publication number: 20030091631
    Abstract: A method of effectively treating pain in humans is achieved by administering buprenorphine in accordance with first order kinetics over an initial three-day dosing interval, such that a maximum plasma concentration from about 20 pg/ml to about 1052 pg/ml is attained, and thereafter maintaining the administration of buprenorphine for at least an additional two-day dosing interval in accordance with substantially zero order kinetics, such that the patients experience analgesia throughout the at least two-day additional dosing interval.
    Type: Application
    Filed: December 27, 2001
    Publication date: May 15, 2003
    Inventors: Robert F. Reder, Paul D. Goldenheim, Robert F. Kaiko
  • Publication number: 20030035837
    Abstract: Patients are treated with 24-hour oral sustained release opioid formulations which, upon administration, provide an initially rapid opioid absorption such that the minimum effective analgesic concentration of the opioid is more quickly achieved. These sustained release opioid formulations include an effective amount of at least one retardant material to cause said opioid analgesic to be released at a such a rate as to provide an analgesic effect after oral administration to a human patient for at least about 24 hours, and are characterized by providing an absorption half-life from 1 to about 8 hours. A method of titrating a human patient utilizing these sustained release opioid formulations is also disclosed.
    Type: Application
    Filed: June 4, 2002
    Publication date: February 20, 2003
    Inventors: Richard S. Sackler, Paul Goldenheim, Robert F. Kaiko
  • Publication number: 20030031712
    Abstract: The invention is directed in part to oral dosage forms comprising a combination of an orally analgesically effective amount of an opioid agonist and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist to provide a combination product which is analgesically effective when the combination is administered orally, but which is aversive in a physically dependent subject. Preferably, the amount of opioid antagonist included in the combination product provides at least a mildly negative, “aversive” experience in physically dependent addicts (e.g., precipitated abstinence syndrome).
    Type: Application
    Filed: September 16, 2002
    Publication date: February 13, 2003
    Inventors: Robert F. Kaiko, Robert D. Colucci
  • Patent number: 6475494
    Abstract: The invention is directed in part to oral dosage forms comprising a combination of an orally analgesically effective amount of an opioid agonist and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist to provide a combination product which is analgesically effective when the combination is administered orally, but which is aversive in a physically dependent subject. Preferably, the amount of opioid antagonist included in the combination product provides at least a mildly negative, “aversive” experience in physically dependent addicts (e.g., precipitated abstinence syndrome).
    Type: Grant
    Filed: March 22, 2001
    Date of Patent: November 5, 2002
    Assignee: Euro-Celtique S.A.
    Inventors: Robert F. Kaiko, Robert D. Colucci
  • Publication number: 20020058050
    Abstract: Patients are treated with 24-hour oral sustained release opioid formulations which, upon administration, provide an initially rapid opioid absorption such that the minimum effective analgesic concentration of the opioid is more quickly achieved. These sustained release opioid formulations include an effective amount of at least one retardant material to cause said opioid analgesic to be released at a such a rate as to provide an analgesic effect after oral administration to a human patient for at least about 24 hours, and are characterized by providing an absorption half-life from 1 to about 8 hours. A method of titrating a human patient utilizing these sustained release opioid formulations is also disclosed.
    Type: Application
    Filed: September 26, 1997
    Publication date: May 16, 2002
    Inventors: RICHARD S. SACKLER, PAUL GOLDENHEIM, ROBERT F. KAIKO
  • Patent number: RE41408
    Abstract: A method of effectively treating pain in humans is achieved by administering buprenorphine in accordance with first order kinetics over an initial three-day dosing interval, such that a maximum plasma concentration from about 20 pg/ml to about 1052 pg/ml is attained, and thereafter maintaining the administration of buprenorphine for at least an addition two-day dosing interval in accordance with substantially zero order kinetics, such that the patients experience analgesia throughout the at least two-day additional dosing interval.
    Type: Grant
    Filed: May 1, 2007
    Date of Patent: June 29, 2010
    Assignee: Purdue Pharma L.P.
    Inventors: Robert F. Reder, Robert F. Kaiko, Paul D. Goldenheim
  • Patent number: RE41489
    Abstract: A method of effectively treating pain in humans is achieved by administering buprenorphinein accordance with first order kinetics over an initial three-day dosing interval, such that a maximum plasma concentration from about 20 pg/ml to about 1052 pg/ml is attained, and thereafter maintaining the administration of buprenorphine for at least an additional two-day dosing interval in accordance with substantially zero order kinetics, such that the patients experience analgesia throughout the at least two-day additional dosing interval.
    Type: Grant
    Filed: May 1, 2007
    Date of Patent: August 10, 2010
    Assignee: Purdue Pharma L.P.
    Inventors: Robert F. Reder, Robert F. Kaiko, Paul D. Goldenheim
  • Patent number: RE41571
    Abstract: A method of effectively treating pain in humans is achieved by administering buprenorphine in accordance with first order kinetics over an initial three-day dosing interval, such that a maximum plasma concentration from about 20 pg/ml to about 1052 pg/ml is attained, and thereafter maintaining the administration of buprenorphine for at least an additional two-day dosing interval in accordance with substantially zero order kinetics, such that the patients experience analgesia throughout the at least two-day additional dosing interval.
    Type: Grant
    Filed: May 1, 2007
    Date of Patent: August 24, 2010
    Assignee: Purdue Pharma L.P.
    Inventors: Robert F. Reder, Robert F. Kaiko, Paul D. Goldenheim